BET3 Inhibitors
BET3 inhibitors encompass a spectrum of chemical compounds that indirectly curtail the functional activity of BET3 through various biochemical pathways and cellular processes. Wortmannin, by targeting PI3K, induces a blockade in the pathways that rely on PI3K signaling, which is essential for the membrane dynamics and vesicular trafficking where BET3 is engaged. Similarly, Rapamycin's suppression of mTOR activity leads to a global downturn in protein synthesis and vesicular transport demand, thereby diminishing the necessity for BET3's role in trafficking. The functionality of BET3 in the Golgi apparatus is compromised by Brefeldin A, which dismantles the Golgi structure by inhibiting ARF1 GTPase, and by Epoxomicin, which perturbs the Golgi's architecture through GBF1inhibition. Additionally, the integrity of the cytoskeleton, which BET3 relies upon for vesicular transport, is impaired by compounds like Nocodazole and Taxol, which disrupt microtubule dynamics in opposing manners, and Cytochalasin D, which impedes actin polymerization. Monensin's disruption of intracellular ion gradients and Tunicamycin's inhibition of N-linked glycosylation further compromise the protein folding and trafficking processes essential for BET3's function in transport.
The intricate interplay between cellular signaling and vesicular trafficking is further influenced by chemicals such as Dynasore, Clotrimazole, and Lithium Chloride. Dynasore's inhibition of the GTPase dynamin diminishes endocytosis and vesicular trafficking, indirectly leading to a decreased functional demand on BET3. Clotrimazole, by altering calcium signaling, affects a critical regulatory step for vesicle fusion, thereby indirectly diminishing BET3's trafficking efficiency. Lithium Chloride's modulation of GSK-3 activity also impacts signaling pathways that intersect with vesicular transport processes involving BET3. These inhibitors, through their targeted effects on cellular structures and signaling mechanisms, collectively contribute to the attenuation of BET3's functional role in intracellular transport without directly affecting the protein's expression.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). BET3's function in vesicular trafficking could be indirectly diminished by Wortmannin through the disruption of PI3K-dependent signaling, which is crucial for membrane dynamics. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that would lead to a reduction in overall protein synthesis and trafficking, indirectly diminishing BET3's functional role in intracellular transport due to the decreased demand for vesicle-mediated processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the ARF1 GTPase, leading to Golgi disassembly. Since BET3 is involved in Golgi-related transport, its function would be indirectly diminished by Brefeldin A through the inhibition of a process that BET3 is indirectly associated with. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase involved in vesicle scission. Inhibiting dynamin can lead to reduced endocytosis and vesicular trafficking, thus indirectly diminishing the functional activity of BET3 related to trafficking. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin acts as an ionophore that disrupts intracellular ion gradients. The alteration in ion balance can lead to dysfunctional vesicular trafficking, indirectly diminishing BET3's role in transport due to the disruption of vesicle pH and charge balance. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization. BET3's role in vesicular trafficking is dependent on the cytoskeleton; thus, nocodazole indirectly diminishes BET3's function by destabilizing the microtubule network required for vesicle transport. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D inhibits actin polymerization. Since BET3 is involved in vesicular transport, the disruption of the actin cytoskeleton by Cytochalasin D can indirectly diminish BET3’s functional role in this process. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation. BET3’s function in vesicular trafficking could be diminished due to the impaired glycosylation of proteins, which is essential for proper folding and trafficking of membrane and secreted proteins. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1). By inhibiting GBF1, Epoxomicin can indirectly diminish BET3's role in trafficking due to the perturbation of Golgi structure and function. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Clotrimazole is known to inhibit calcium and potassium channels. By disrupting calcium signaling, it can indirectly diminish BET3's function, as calcium signaling is important for various steps in vesicular fusion and trafficking. | ||||||